860654P

sphinganine (d17:0)

Avanti Research^™ - A Croda Brand 860654P, powder

• 同義詞: D-erythro-sphinganine (C17 base)
• 經驗公式（希爾表示法）: C₁₇H₃₇NO₂
• CAS號碼: 32164-02-6
• 分子量：: 287.48
• MDL號碼: MFCD22416605
• 分類程式碼代碼: 12352211
• NACRES: NA.25

屬性

• 形狀: powder
• 包裝: pkg of 1 × 10 mg (860654P-10mg); pkg of 1 × 5 mg (860654P-5mg)
• 製造商／商標名: Avanti Research^™ - A Croda Brand 860654P
• 脂質類型: sphingolipids
• 運輸包裝: dry ice
• 儲存溫度: −20°C
• SMILES 字串: OC[C@@](N)([H])[C@]([H])(O)CCCCCCCCCCCCCC
• InChI: 1S/C17H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-17(20)16(18)15-19/h16-17,19-20H,2-15,18H2,1H3/t16-,17+/m0/s1
• InChI 密鑰: KFQUQCFJDMSIJF-DLBZAZTESA-N

描述

一般說明

Sphinganine (d17:0), also referred to as dihydrosphingosine, is devoid of double bond. Decarboxylating condensation of serine with palmitoyl-CoA yield keto intermediate(2-oxosphinganine), which is then reduced by NADPH to form Sphinganine.

應用

Sphinganine (d17:0) has been used in liquid chromatography-mass spectrometry (LC-MS) for the in-situ estimation of dihydrosphingosine utilization in N-(4-hydroxyphenyl)retinamide (4-HPR) resistant leukemia cells. It is suitable for use as an internal standard in metabolomic study.

生化／生理作用

Sphinganine (SPA) or D-erythro-sphinganine is involved in sphingolipid biosynthesis pathway. It acts as a precursor for ceramide. SPA has an ability to inhibit the activity of protein kinase c. SPA accumulation enables fumonisin B1 to stimulate apoptosis. It also has an ability to block cholesterol transport in Niemann-Pick Type C (NPC) disease.

包裝

5 mL Amber Glass Screw Cap Vial (860654P-10mg)

5 mL Amber Glass Screw Cap Vial (860654P-5mg)

法律資訊

Avanti Research is a trademark of Avanti Polar Lipids, LLC

安全資訊

• 儲存類別代碼: 11 - Combustible Solids
• 水污染物質分類（WGK）: WGK 3